A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy for unresectable head and neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 2, 1999, Pages 311-315

  MacHtay, M ^a   Aviles, V ^a   Kligerman, M M ^a   Treat, J ^a   Weinstein, G S ^a   Weber, R S ^a   Mirza, N ^a   Chalian, A A ^a   Rosenthal, D I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Accelerated radiotherapy; Concurrent chemoradiotherapy; Head and neck cancer; Paclitaxel

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; RADIATION-SENSITIZING AGENTS; STOMATITIS;

EID: 0032913649     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00027-9     Document Type: Article

References (18)

1. Merlano M., Vitale V., Rosso R., et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med. 327:1992;1115-1121.
2. Parsons J.T., Mendenhall W.M., Stringer S.P., et al. Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck The University of Florida experience . Head Neck. 15:1993;87.
3. Munro A.J. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 71:1995;83-91.
4. Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methorexate. J Clin Oncol. 10:1992;1245-1251.
5. Forastiere AA, Leong T, Murphy B; et al. A phase III trial of high-dose paclitaxel + cisplatin + G-CSF vs. low-dose paclitaxel + cisplatin in patients with advanced squamous cell carcinoma of the the head and neck (HNSCC): An ECOG trial (Abstr. #1367). Proc Am Soc Clin Oncol 1997, p 384.
6. Leonard C., Chan D.C., Chou T.C., et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res. 56:1996;5198-5204.
7. Glantz M.J., Choy H., Akerly W., et al. Weekly paclitaxel with and without concurrent radiation therapy Toxicity, pharmacokinetics, and response . Semin Oncol. 23:1996;123-125.
8. Socinski M.A., Mudd P.N.J., Radomski K.M., Steagall A., Lawrence P., Bernard S., Letrent S.P., Gonzalez P., Brouwer K.L. Phase I trial of a 96-hr paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anticancer Drugs. 9:1998;611-619.
9. Zanelli G.D., Quaia M., Robieux I., et al. Paclitaxel as a radiosensitizer A proposed schedule of administration based on in vitro data and pharmacokinetic calculations . Eur J Cancer. 33:1997;486-492.
10. Georgiadis M.S., Schuler B.S., Brown J.E., Kieffer L.V., Steinberg S.M., Wilson W.H., Takimoto C.H., Kelley M.J., Johnson B.E. Paclitaxel by 96-hour continuous infusion in combination with cisplatin A phase I trial in patients with advanced lung cancer . J Clin Oncol. 15:1997;735-743.
11. Wilson W.H., Berg S.L., Bryant G., Wittes R.E., Bates S., et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer A phase I/II trial of 96-hour infusion . J Clin Oncol. 12:1994;1621-1629.
12. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
13. Huang K., Vaughn D.J., Shaw L.M., Recio A., Bonner H.S., Haller D.G. A phase II trial and pharmacokinetic analysis of 96-hour infusional paclitaxel in patients with metastatic colorectal cancer. Am J Clin Oncol. 21:1998;548-552.
14. Flood WA, Lee DJ, Trotti A; et al. A phase I study of weekly paclitaxel and cisplatin concurrent with postoperative radiation therapy for treatment of high-risk patients with squamous cell cancer of the head and neck (Abstr. #885). Proc Am Soc Clin Oncol 1996, p 314.
15. Brockstein B., Haraf D.J., Stenson K., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with G-CSF support for patients with poor prognosis cancer of the head and neck. J Clin Oncol. 16:1998;735-744.
16. Kroog G.S., Van Waes C., Thomas G., et al. A pilot study of 120-hour paclitaxel with radiation therapy for locally advanced head and neck cancer (Abstr. #1528). Proc Am Soc Clin Oncol. 17:1998;396.
17. Rosenthal D.L., Okani O., Truelson J.M., et al. Intensive radiation therapy concurrent with up to 7-week continuous infusion paclitaxel for locally advanced solid tumors Phase I studies . Semin Oncol. 24:1997;81-84.
18. Plasswilm L., Kirschner M., Suer R. Concurrent taxol and split-course accelerated radiotherapy for advanced head and neck cancer. Strahlen Onkol. 172:1996;573-579.